Ms Sarah Taylor

Sarah Taylor

Updates

Healthcare & Life Sciences

Life sciences patent bargain front and centre in Regeneron v Kymab
United Kingdom | 22 July 2020

The recent Supreme Court decision in Regeneron v Kymab has highlighted the risk-reward dynamic that exists for pharmaceutical and biotechnology companies that seek patent protection for innovations early in the discovery process. The court found that if a claimed patent monopoly defines a whole range of products, all of the products within the 'relevant range' must be appropriately enabled by the patent specification. This decision is of great importance to the biotechnology and wider life sciences sector.